Literature DB >> 12885880

Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity.

Karidia Diallo1, Bruno Marchand, Xin Wei, Luciano Cellai, Matthias Götte, Mark A Wainberg.   

Abstract

The emergence of drug resistance-conferring mutations can severely compromise the success of chemotherapy directed against human immunodeficiency virus type 1 (HIV-1). The M184V and/or L74V mutation in the reverse transcriptase (RT) gene are frequently found in viral isolates from patients treated with the nucleoside RT inhibitors lamivudine (3TC), abacavir (ABC), and didanosine (ddI). However, the effectiveness of combination therapy with regimens containing these compounds is often not abolished in the presence of these mutations; it has been conjectured that diminished fitness of HIV-1 variants containing L74V and M184V may contribute to sustained antiviral effects in such cases. We have determined that viruses containing both L74V and M184V are more impaired in replication capacity than viruses containing either mutation alone. To understand the biochemical mechanisms responsible for this diminished fitness, we generated a series of recombinant mutated enzymes containing either or both of the L74V and M184V substitutions. These enzymes were tested for their abilities to bypass important rate-limiting steps during the complex process of reverse transcription. We studied both the initiation of minus-strand DNA synthesis with the cognate replication primer human tRNA(3)(Lys) and the initiation of plus-strand DNA synthesis, using a short RNA primer derived from the viral polypurine tract. We observed that the efficiencies of both reactions were diminished with enzymes containing either L74V or M184V and that these effects were significantly amplified with the double mutant. We also show that release from intrinsic pausing sites during reverse transcription appears to be a major obstacle that cannot be efficiently bypassed. Our data suggest that the efficiency of RNA-primed DNA synthesis represents an important consideration that can affect viral replication kinetics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12885880      PMCID: PMC167213          DOI: 10.1128/jvi.77.16.8621-8632.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses.

Authors:  Xin Wei; Chen Liang; Matthias Götte; Mark A Wainberg
Journal:  AIDS       Date:  2002-12-06       Impact factor: 4.177

2.  Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1.

Authors:  M Hsu; P Inouye; L Rezende; N Richard; Z Li; V R Prasad; M A Wainberg
Journal:  Nucleic Acids Res       Date:  1997-11-15       Impact factor: 16.971

3.  Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.

Authors:  R F Schinazi; R M Lloyd; M H Nguyen; D L Cannon; A McMillan; N Ilksoy; C K Chu; D C Liotta; H Z Bazmi; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

4.  pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.

Authors:  J J Eron; Y K Chow; A M Caliendo; J Videler; K M Devore; T P Cooley; H A Liebman; J C Kaplan; M S Hirsch; R T D'Aquila
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

5.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA.

Authors:  A Jacobo-Molina; J Ding; R G Nanni; A D Clark; X Lu; C Tantillo; R L Williams; G Kamer; A L Ferris; P Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

6.  Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir.

Authors:  Adrian S Ray; Aravind Basavapathruni; Karen S Anderson
Journal:  J Biol Chem       Date:  2002-08-09       Impact factor: 5.157

7.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.

Authors:  H Huang; R Chopra; G L Verdine; S C Harrison
Journal:  Science       Date:  1998-11-27       Impact factor: 47.728

8.  Mechanism and fidelity of HIV reverse transcriptase.

Authors:  W M Kati; K A Johnson; L F Jerva; K S Anderson
Journal:  J Biol Chem       Date:  1992-12-25       Impact factor: 5.157

9.  Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.

Authors:  Z Gu; Q Gao; H Fang; H Salomon; M A Parniak; E Goldberg; J Cameron; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

10.  Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction.

Authors:  E J Arts; X Li; Z Gu; L Kleiman; M A Parniak; M A Wainberg
Journal:  J Biol Chem       Date:  1994-05-20       Impact factor: 5.157

View more
  14 in total

Review 1.  Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Mark A Wainberg; Bluma G Brenner; Dan Turner
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

2.  Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients.

Authors:  Marc Wirden; Bénédicte Roquebert; Anne Derache; Anne Simon; Claudine Duvivier; Jade Ghosn; Stephanie Dominguez; Véronique Boutonnet; Zaina Ait-Arkoub; Christine Katlama; Vincent Calvez; Anne-Genevieve Marcelin
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.

Authors:  Francine Bouchonnet; Elisabeth Dam; Fabrizio Mammano; Vaea de Soultrait; Gaëlle Henneré; Henri Benech; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1.

Authors:  Thomas A Toni; Bluma G Brenner; Eugene L Asahchop; Michel Ntemgwa; Daniella Moisi; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

5.  Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture.

Authors:  Marco Petrella; Maureen Oliveira; Daniela Moisi; Mervi Detorio; Bluma G Brenner; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

6.  The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.

Authors:  Hong-Tao Xu; Yudong Quan; Susan M Schader; Maureen Oliveira; Tamara Bar-Magen; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

7.  Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Fernando A Frankel; Bruno Marchand; Dan Turner; Matthias Götte; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

8.  Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection.

Authors:  Thomas A Toni; Eugene L Asahchop; Daniela Moisi; Michel Ntemgwa; Maureen Oliveira; Bernard Masquelier; Bluma G Brenner; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

9.  Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.

Authors:  Hongtao Xu; Yudong Quan; Bluma G Brenner; Tamara Bar-Magen; Maureen Oliveira; Susan M Schader; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

10.  Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.

Authors:  Michel Ntemgwa; Mark A Wainberg; Maureen Oliveira; Daniela Moisi; Richard Lalonde; Valeria Micheli; Bluma G Brenner
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.